248 results on '"Roque, Dana M."'
Search Results
2. Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids
3. Tubulin Complexity in Cancer and Metastasis
4. Microtubule-Targeting Agents: Disruption of the Cellular Cytoskeleton as a Backbone of Ovarian Cancer Therapy
5. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
6. In vitro fertilization: a cross-sectional analysis of 58 US insurance companies
7. Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases
8. Transient fluid flow improves photoimmunoconjugate delivery and photoimmunotherapy efficacy
9. Clinical Outcomes of Intensity Modulated Proton Therapy Reirradiation for Gynecologic Malignancies
10. Overview of Ovarian Cancer Chemotherapy
11. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
12. Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu
13. Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy
14. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum- resistant or refractory ovarian / fallopian tube / primary peritoneal cancer (NCT03093155): updated survival and subgroup analyses
15. Early Implementation of Robotic Training in Surgical and Surgical Subspecialty Residency
16. Future Directions and New Targets in Endometrial Cancer
17. Fluorescence-guided photoimmunotherapy using targeted nanotechnology and ML7710 to manage peritoneal carcinomatosis
18. Malignant Sex Cord-Stromal Tumor, Not Otherwise Specified, Harboring FOXL2, p53, and TERT Promoter Mutations: Report of a Case
19. Ovarian Tumor Microenvironment and Innate Immune Recognition
20. Figure S1 Full Protocol from Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis
21. The role of fluid shear stress in regulating photoimmunotherapy efficacy and immunogenic cell death (Conference Presentation)
22. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review
23. Use of Monsel solution to treat obstetrical hemorrhage: a review and comparison to other topical hemostatic agents
24. Clinical Outcomes of Intensity Modulated Proton Therapy (IMPT) Re-Irradiation for Gynecologic Malignancies
25. In vitro fertilization: a cross-sectional analysis of 58 US insurance companies
26. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo
27. Application of Serum and Tissue Proteomics to Understand and Detect Solid Tumors
28. Review of Immune Therapies Targeting Ovarian Cancer
29. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma
30. Differential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expression
31. Pap smear outcomes in elderly women living with HIV and HIV-negative matched controls
32. Appearances can be deceiving: Ovarian mass presents as vaginal prolapse
33. Microtentacle Formation in Ovarian Carcinoma
34. Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment
35. A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability
36. Reply
37. Risk, risk reduction and management of occult malignancy diagnosed after uterine morcellation: a commentary
38. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel
39. Future Directions and New Targets in Endometrial Cancer
40. HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies
41. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone
42. Photodynamic Priming Improves the Anti-Migratory Activity of Prostaglandin E Receptor 4 Antagonist in Cancer Cells In Vitro
43. Solitomab, an Epithelial Cell Adhesion Molecule/CD3 Bispecific Antibody (BiTE), Is Highly Active Against Primary Chemotherapy-Resistant Ovarian Cancer Cell Lines in Vitro and Fresh Tumor Cells Ex Vivo
44. Past, present and future targets for immunotherapy in ovarian cancer
45. Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response
46. Photodynamic Priming Improves the Anti-Migratory Activity of Prostaglandin E Receptor 4 Antagonist in Cancer Cells In Vitro
47. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
48. A novel small molecule LLL12B inhibits STAT3 signaling and sensitizes ovarian cancer cell to paclitaxel and cisplatin
49. Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer
50. Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.